- Home
- MPLN vs AGEN Comparison
MPLN vs AGEN Comparison
Compare MPLN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPLN
- AGEN
- Stock Information
- Founded
- MPLN 1980
- AGEN 1994
- Country
- MPLN United States
- AGEN United States
- Employees
- MPLN N/A
- AGEN N/A
- Industry
- MPLN Business Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPLN Consumer Discretionary
- AGEN Health Care
- Exchange
- MPLN Nasdaq
- AGEN Nasdaq
- Market Cap
- MPLN 99.9M
- AGEN 96.2M
- IPO Year
- MPLN N/A
- AGEN 2000
- Fundamental
- Price
- MPLN $7.00
- AGEN $3.34
- Analyst Decision
- MPLN Hold
- AGEN Buy
- Analyst Count
- MPLN 2
- AGEN 3
- Target Price
- MPLN $25.00
- AGEN $9.33
- AVG Volume (30 Days)
- MPLN 84.7K
- AGEN 638.9K
- Earning Date
- MPLN 11-05-2024
- AGEN 11-12-2024
- Dividend Yield
- MPLN N/A
- AGEN N/A
- EPS Growth
- MPLN N/A
- AGEN N/A
- EPS
- MPLN N/A
- AGEN N/A
- Revenue
- MPLN $942,614,000.00
- AGEN $160,427,000.00
- Revenue This Year
- MPLN N/A
- AGEN N/A
- Revenue Next Year
- MPLN $1.07
- AGEN $0.04
- P/E Ratio
- MPLN N/A
- AGEN N/A
- Revenue Growth
- MPLN N/A
- AGEN 59.00
- 52 Week Low
- MPLN $4.80
- AGEN $2.50
- 52 Week High
- MPLN $69.20
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- MPLN 41.66
- AGEN 42.62
- Support Level
- MPLN $4.80
- AGEN $2.50
- Resistance Level
- MPLN $9.15
- AGEN $2.89
- Average True Range (ATR)
- MPLN 0.91
- AGEN 0.32
- MACD
- MPLN -0.14
- AGEN -0.01
- Stochastic Oscillator
- MPLN 49.89
- AGEN 43.75
About MPLN MultiPlan Corporation
MultiPlan Corp is a provider of data analytics and technology-enabled solutions designed to bring affordability, efficiency, and fairness to the U.S. healthcare industry. The company interprets clients' needs and customizes solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).